Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.

Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.

GlaxoSmithKline (GSK) is currently conducting a Phase 4 clinical study titled ‘A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered ...

PHILADELPHIA, June 24, 2025--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte ...

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

Belimumab is under clinical development by GSK and currently in Phase II for Cryoglobulinemia. According to GlobalData, Phase II drugs for Cryoglobulinemia does not have sufficient historical data to ...

Belimumab demonstrated superior efficacy vs placebo for achieving remission and low disease activity status among patients with active SLE.

Belimumab substantially increases circulating memory B-cells in patients with systemic lupus erythematosus, potentially enabling “a more efficient targeting of the B-cell compartment ...

HealthDay News — The US Food and Drug Administration has approved a 200 mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic ...

The Belimumab market survey report conducts a market study that takes into account diverse markets tailored to the specific needs of the Belimumab industry. Belimumab market is expected to gain market ...